Protein pathway activation associated with sustained virologic response in patients with chronic hepatitis C treated with pegylated interferon (PEG-IFN) and ribavirin (RBV)

Journal of Proteome Research

Volumn 10, Issue 2, 2011, Pages 774-779

  Younossi, Zobair M ^a   Limongi, Dolores ^b   Stepanova, Maria ^a   Pierobon, Mariaelena ^b   Afendy, Arian ^a   Mehta, Rohini ^a,b   Baranova, Ancha ^a,b   Liotta, Lance ^b   Petricoin, Emanuel ^b  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b GEORGE MASON UNIVERSITY   (United States)

Author keywords

Chronic Hepatitis C (CH C); Proteomics profiling; Sustained Virologic Response (SVR)

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CD5 ANTIGEN; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; JANUS KINASE 1; PEGINTERFERON; PROTEIN HYDROLYSATE; PROTEIN KINASE B; PROTEIN KINASE C LAMBDA; PROTEIN KINASE C ZETA; PROTEIN KINASE LCK; PROTEIN KINASE TYK2; PROTEIN KINASE ZAP 70; RIBAVIRIN; S6 KINASE; STAT2 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; IMMUNOCOMPETENT CELL; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEOMICS; REGRESSION ANALYSIS; REVERSE PHASE PROTEIN MICROARRAY; SENSITIVITY AND SPECIFICITY; SUSTAINED VIROLOGIC RESPONSE; TREATMENT RESPONSE; VIRUS GENOME; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; AREA UNDER CURVE; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERFERON TYPE I; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; PHOSPHOPROTEINS; POLYETHYLENE GLYCOLS; PROTEIN ARRAY ANALYSIS; PROTEOMICS; RECOMBINANT PROTEINS; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; RIBAVIRIN; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; STATISTICS, NONPARAMETRIC;

HEPATITIS C VIRUS;

EID: 79955432032     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr100923u     Document Type: Article

References (32)

1. Alter, M. J. Epidemiology of hepatitis C virus infection. World I. Gastroenterol. 2007, 13, 2436-41. (Pubitemid 46929498)
2. Tan, J.; Lok, A. S. Update on viral hepatitis: 2006. Curr. Opin. Gastroenterol. 2007, 23, 263-7. (Pubitemid 46573141)
3. Manns, M. P.; McHutchison, J. G.; Gordon, S. C.; et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358 (9286), 958-65. (Pubitemid 32913521)
4. Fried, M. W.; Shiffman, M. L.; Reddy, K. R.; et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002, 347, 975-8.
5. Hadziyannis, S. J.; Cheinquer, H.; Morgan, T.; et al. Peginterferon alfa-2a (40KD) in combination with ribavirin: efficacy and safety results from a phase III randomized, double-blind multicenter study examining the effect of duration of treatment and RBV dose. J. Hepatol. 2002, 36,3.
6. Bowden, D. S.; Berzsenyi, M. D. Chronic hepatitis C virus infection: genotyping and its clinical role. Future Microbiol. 2006, 1, 103-12.
7. Darling, J. M.; Fried, M. W. Optimizing treatment regimens in hepatitis C. Clin. Liver Dis. 2006, 10, 835-50. (Pubitemid 44880159)
8. Timm, J.; Roggendorf, M. Sequence diversity of hepatitis C virus: implications for immune control and therapy. World J. Gastroenterol. 2007, 13, 4808-17. (Pubitemid 47496745)
9. Wohnsland, A.; Hofmann, W. P.; Sarrazin, C. Viral determinants of resistance to treatment in patients with hepatitis C. Clin. Microbiol. Rev. 2007, 20, 23-38. (Pubitemid 46167766)
10. Neumann-Haefelin, C; Spangenberg, H. C.; Blum, H. E.; Thimme, R. Host and viral factors contributing to CD8+ T cell failure in hepatitis C virus infection. World J. Gastroenterol. 2007, 13, 4839-47. (Pubitemid 47496749)
11. Chen, T. Y.; Hsieh, Y. S.; Wu, T. T.; Yang, S. F.; Wu, C. J.; Tsay, G. J.; Chiou, H. L. Impact of serum levels and gene polymorphism of cytokines on chronic hepatitis C infection. Transl. Res. 2007, 150, 116-21. (Pubitemid 47081450)
12. Bondini, S.; Younossi, Z. M. Non-alcoholic fatty liver disease and hepatitis C infection. Minerva Dietol. Gastroenterol. 2006, 52, 135-43. (Pubitemid 43774323)
13. Sharma, P.; Marrero, J. A.; Fontana, R. J.; Greenson, J. K.; Conjeevaram, H.; Su, G. L.; Askari, F.; Sullivan, P.; Lok, A. S. Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence. Liver Transpl. 2007, 13, 1100-8. (Pubitemid 47305028)
14. Mulhall, B. P.; Younossi, Z. Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C. J. Clin. Gastroenterol. 2005, 39, S23-7. (Pubitemid 40024234)
15. Birerdinc, A.; Afendy, A.; Stepanova, M.; Younossi, I.; Manyam, G.; Baranova, A.; Younossi, Z. M. Functional pathway analysis of genes associated with response to treatment for chronic hepatitis C. J Viral Hepat. 2010, 17, 730-6.
16. Younossi, Z. M.; Baranova, A.; Afendy, A.; Collantes, R.; Stepanova, M.; Manyam, G.; Bakshi, A.; Sigua, C. L.; Chan, J. P.; Iverson, A. A.; Santini, C. D.; Chang, S. Y. Early gene expression profiles of patients with chronic hepatitis C treated with pegylated interferonalfa and ribavirin. Hepatology 2009, 49 (3), 763-74.
17. Huang, T.; Tu, K.; Shyr, Y.; Wei, C. C.; Xie, L.; Li, Y. X. The prediction of interferon treatment effects based on time series microarray gene expression profiles. J. Transl. Med. 2008, 6, 44.
18. Bustin, S. A.; Mueller, R. Real-time reverse transcription PCR (qRT-PCR) and its potential use in clinical diagnosis. Clin. Sci. 2005, 109 (4), 365-79. (Pubitemid 41445244)
19. Pierobon, M.; Calvert, V.; Belluco, C.; Garaci, E.; Deng, J.; Lise, M.; Nitti, D.; Mammano, E.; Marchi, F. D.; Liotta, L.; Petricoin, E. Multiplexed cell signaling analysis of metastatic and nonmetastatic colorectal cancer reveals COX2-EGFR signaling activation as a potential prognostic pathway biomarker. Clin. Colorectal. Cancer 2009, 8 (2), 110-7.
20. Calvert, V. S.; Collantes, R.; Elariny, H.; Afendy, A.; Baranova, A.; Mendoza, M.; Goodman, Z.; Liotta, L. A.; Petricoin, E. F.; Younossi, Z. M. A systems biology approach to the pathogenesis of obesityrelated nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis. Hepatology 2007, 46 (1), 166-72. (Pubitemid 47171933)
21. Wulfkuhle, J. D.; Speer, R.; Pierobon, M.; Laird, J.; Espina, V.; Deng, J.; Mammano, E.; Yang, S. X.; Swain, S. M.; Nitti, D.; Esserman, L. J.; Belluco, C.; Liotta, L. A.; Petricoin, E. F. Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J. Proteome Res. 2008, 7 (4), 1508-17.
22. Huang, C.; Chen, H.; Cassidy, W.; Howell, C. D. Peripheral blood gene expression profile associated with sustained virologic response after peginterferon plus ribavirin therapy for chronic hepatitis-C genotype 1. J. Natl. Med. Assoc. 2008, 100 (12), 1425-33.
23. Antonelli, A.; Ferri, C.; Ferrari, S. M.; Ghiri, E.; Marchi, S.; Colaci, M.; Bruschi, F.; Fallahi, P. High interleukin-6 and tumor necrosis factor-alpha serum levels in hepatitis C infection associated or not with mixed cryoglobulinemia. Clin. Rheumatol. 2009, 28 (10), 1179-85.
24. Loftis, J. M.; Huckans, M.; Ruimy, S.; Hinrichs, D. J.; Hauser, P. Depressive symptoms in patients with chronic hepatitis C are correlated with elevated plasma levels of interleukin-1beta and tumor necrosis factor-alpha. Neurosci. Lett. 2008, 430 (3), 264-8.
25. Haybaeck, J.; Zeller, N.; Wolf, M. J.; Weber, A.; Wagner, U.; Kurrer, M. O.; Bremer, J.; Iezzi, G.; Graf, R.; Clavien, P. A.; Thimme, R.; Blum, H.; Nedospasov, S. A.; Zatloukal, K.; Ramzan, M.; Ciesek, S.; Pietschmann, T.; Marche, P. N.; Karin, M.; Kopf, M.; Browning, J. L.; Aguzzi, A.; Heikenwalder, M. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell. 2009, 16 (4), 295-308.
26. Dai, C. Y.; Chuang, W. L.; Chang, W. Y.; Chen, S. C.; Lee, L. P.; Hsieh, M. Y.; Hou, N. J.; Lin, Z. Y.; Huang, J. F.; Hsieh, M. Y.; Wang, L. Y.; Yu, M. L. Tumor necrosis factor-alpha promoter polymorphism at position-308 predicts response to combination therapy in hepatitis C virus infection. J. Infect. Dis. 2006, 193 (1), 98-101.
27. Kang, S. M.; Kim, S. J.; Kim, J. H.; Lee, W.; Kim, G. W.; Lee, K. H.; Choi, K. Y.; Oh, J. W. Interaction of hepatitis C virus core protein with Hsp60 triggers the production of reactive oxygen species and enhances TNF-alpha-mediated apoptosis. Cancer Lett. 2009, 279 (2), 230-7.
28. Rigopoulou, E. I.; Abbott, W. G.; Williams, R.; Naoumov, N. V. Direct evidence for immunomodulatory properties of ribavirin on T-cell reactivity to hepatitis C virus. Antiviral Res. 2007, 75 (1), 36-42. (Pubitemid 46610522)
29. Martin-Blondel, G.; Gales, A.; Bernad, J.; Cuzin, L.; Delobel, P.; Barange, K.; Izopet, J.; Pipy, B.; Alric, L. Low interleukin-10 production by monocytes of patients. J. Viral. Hepat. 2009, 16 (7), 485-91.
30. Rayasam, G. V.; Tulasi, V. K.; Sodhi, R.; Davis, J. A.; Ray, A. Glycogen synthase kinase 3: more than a namesake. Br. J. Pharmacol. 2009, 156, 885-898.
31. Wagman, A. S.; Johnson, K. W.; Bussiere, D. E. Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. Curr. Pharm. Des. 2004, 10, 1105-1137.
32. Hazari, S.; Taylor, L.; Haque, S.; Garry, R. F.; Florman, S.; Luftig, R.; Regenstein, F.; Dash, S. Reduced expression ofJak-1 and Tyk-2 proteins leads to interferon resistance in hepatitis C virus replicon. Virol. J. 2007, 4, 89.